Compare DexCom, Inc. (DXCM) vs F.N.B. Corporation Common Stock (FNB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs F.N.B. Corporation Common Stock — how do they compare? DexCom, Inc. trades at $85.57 (market cap $31.51B), while F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.03B). The key difference: DexCom, Inc. is far larger — about 5.2× F.N.B. Corporation Common Stock's market cap, and F.N.B. Corporation Common Stock pays a 3.07% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and F.N.B. Corporation Common Stock for 0 Days on average.
| DXCM | FNB | |
|---|---|---|
Market Cap | $31.51B | $6.03B |
Volume | 3,480,291 | 7,117,178 |
Sector | Health | Financials |
52-Week High | $92.34 | $19.49 |
52-Week Low | $54.84 | $14.65 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $30.96B | $10.52B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $85.06, down 1.0% on the day, with a bullish technical signal and strong fundamental growth. Revenue reached $4.66B in 2025 with a net income margin of 17.93%, and the company has beaten EPS estimates for the last three quarters. Recent news highlights expansion in Type 2 diabetes care and executive promotions, supporting positive sentiment.
The outlook is positive with a consensus price target of $96.14, implying 13% upside. Risks include competition and reimbursement challenges, but robust earnings growth and institutional backing provide a solid foundation for long-term investors.
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →
